VivoSeq
Cardiovascular

Tricuspid Valve Regurgitation

1

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Tricuspid Valve Regurgitation is an early-stage landscape with 1 program across 2 companies. The most active players are Jiangsu Trulive Medical Co., Ltd, Laplace Interventional, Inc.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Jiangsu Trulive Medical Co., Ltd

0 programs

PreclinicalL

Laplace Interventional, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Optimal Medical Therapy

Helios Health Institute GmbH

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

A Prospective, Multicenter, Randomized Controlled Clinical Trial Protocol Evaluating the Safety and Efficacy of the TruGamma Transcatheter Tricuspid Valve System in Patients With Severe Tricuspid Regurgitation
Recruiting·JJiangsu Trulive Medical Co., Ltd·Preclinical·NCT07691307·180 enrolled
Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System
Not yet recruiting·LLaplace Interventional, Inc·Preclinical·NCT07687485·700 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)